Exagen Inc. (XGN) Misses Q4 EPS by 6c, Revenue Beats, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts XGN Hot Sheet
Join SI Premium – FREE
Exagen Inc. (NASDAQ: XGN) reported Q4 EPS of ($0.83), $0.06 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $8.66 million.
GUIDANCE:
Exagen Inc. sees Q1 2023 revenue of $9.2-9.7 million, versus the consensus of $9.3 million.
For earnings history and earnings-related data on Exagen Inc. (XGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- L.B. Foster (FSTR) Reports In-Line Q3 EPS ; Offers Guidance
- Twin Disc (TWIN) Tops Q1 EPS by 13c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
